Current Edition

Upcoming Events


Building a Gene Therapy: Challenges and Changes in Viral Vector Manufacture

Retroviruses were an attractive first choice for viral vectors for gene therapy because the DNA they encode – either wildtype viral DNA or the therapeutic transgene – becomes integrated into the host cell genome. Dr. Sophie Lutter at OXGENE outlines the challenges and changes in viral sector manufacturing when building a gene therapy.

[wonderplugin_pdf src=”” width=”100%” height=”900px” style=”border:0;”]